Skip to content
Mafodotin
Blenrep (mafodotin) is a small molecule pharmaceutical. Mafodotin was first approved as Blenrep on 2020-08-25. It has been approved in Europe to treat multiple myeloma. It is known to target tumor necrosis factor receptor superfamily member 17.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
blenrepBiologic Licensing Application2020-08-05
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FX: Other monoclonal antibodies and antibody drug conjugates in atc
— L01FX15: Belantamab mafodotin
HCPCS
Code
Description
J9037
Injection, belantamab mafodotin-blmf, 0.5 mg
Clinical
Clinical Trials
53 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101C90.022225—337
GlioblastomaD005909EFO_0000515—12——3
GliosarcomaD018316——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8033———3
Hematologic diseasesD006402EFO_0005803D75.933———3
Blood protein disordersD00179633———3
Plasma cell neoplasmsD05421933———3
ParaproteinemiasD010265D47.233———3
Corneal diseasesD003316H18.933———3
Immunoglobulin light-chain amyloidosisD00007536312———2
Follicular lymphomaD008224C82—2———2
Large b-cell lymphoma diffuseD016403C83.3—2———2
Plasmablastic lymphomaD000069293C83.3—1———1
Show 2 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMAFODOTIN
INNbelantamab mafodotin
Description
Monomethyl auristatin F (MMAF) is a synthetic antineoplastic agent. It is part of the approved drug belantamab mafodotin in multiple myeloma and some experimental anti-cancer antibody-drug conjugates such as vorsetuzumab mafodotin and SGN-CD19A. In International Nonproprietary Names for MMAF-antibody-conjugates, the name mafodotin refers to MMAF plus its attachment structure to the antibody.
Classification
Small molecule
Drug classsynthetic analogs of the dolastatin series
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(=O)C=CC1=O)C(C)C
Identifiers
PDB—
CAS-ID745017-94-1
RxCUI—
ChEMBL IDCHEMBL2107813
ChEBI ID—
PubChem CID10395173
DrugBank—
UNII IDDB1041CXDG (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
TNFRSF17
TNFRSF17
Organism
Homo sapiens
Gene name
TNFRSF17
Gene synonyms
BCM, BCMA
NCBI Gene ID
608
Protein name
tumor necrosis factor receptor superfamily member 17
Protein synonyms
B cell maturation antigen, B-cell maturation factor, B-cell maturation protein, CD269
Uniprot ID
Q2TQ40
Mouse ortholog
Tnfrsf17 (21935)
tumor necrosis factor receptor superfamily member 17 (O88472)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 825 documents
View more details
Safety
Black-box Warning
Black-box warning for: Blenrep
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
5 adverse events reported
View more details